Olive Leaf Extracts in the Control of Hypertension

Efficacy of a Treatment Based on Olive Leaf Extracts in the Control of Cardiovascular Risk Factors:Hypertension

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05636826

Acronym

Atherolive

Enrollment

500

Registered

2022-12-05

Start date

2023-12-30

Completion date

2025-12-30

Last updated

2026-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

hypertension

Brief summary

This study will be carried out in 2 emergency departments (at the exit of the emergency room) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital). Patients over 18 years of age with: Arterial hypertension (hypertension).

Detailed description

This study will be carried out in 2 emergency departments (at the exit of the emergency room, patients included in the GR2 study) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital). All the population will benifit of a biological assessment which include: Complete lipid profile, blood sugar, creatinine one population will be randomized: The population of patients with hypertension. For patients in the hypertension group: A blood pressure with holter will be carried out for 24 hours .

Interventions

DRUGatherolive-drug

The patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.

DRUGPlacebo Atherolive

The patient will be assigned to one of two treatments using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. Placebo will be prescribed at a dose of 400 mg, once a day for 3 months.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 95 Years

Healthy volunteers

Inclusion criteria

* patients over 18 years of age with: Arterial hypertension (hypertension)

Exclusion criteria

* .

Design outcomes

Primary

Measure	Time frame	Description
rate of blood pressure reduction	90 days	blood pressure reduction on 24 hours holter

Secondary

Measure	Time frame	Description
rate of lipid balance variation The secondary endpoint	90 days	variation in lipid reduction balance

Countries

Tunisia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 8, 2026